KBC Group
STOK icon

KBC Group’s Stoke Therapeutics STOK Stock Holding History

KBC Group’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36K Buy
+1,096
New +$35.9K ﹤0.01% 1752

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

KBC Group's STOK Position: Q1 2026 in Review

KBC Group opened a new position in Stoke Therapeutics (STOK) in Q1 2026: 1,096 shares worth $36K. The stake represents ﹤0.01% of the portfolio and ranks #1752 among its holdings.

196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • KBC Group held 1,096 shares of Stoke Therapeutics worth $36K as of Q1 2026.
  • Stoke Therapeutics was a new KBC Group position in Q1 2026.
  • Stoke Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1752 holding.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.